Drugs / CODIVIR
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT04930861 | Mar → May 2021 | COVID-19 | Code Pharma | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06676410 | Jul 2023 → Dec 2024 overdue | HIV infectious disease | Code Pharma | Recruiting | No outcome recorded |
| Phase 2 | NCT05218356 | Jan 2022 → Dec 2024 overdue | COVID-19 | Code Pharma | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2021-09-01 | Code Pharma | Results Antiviral drug Codivir shows promising effect against COVID-19 codepharma.com ↗
The results of the study showed that Codivir has a high safety profile while significantly suppressing viral replication in most of the fully assessed patients with an antiviral effect noted as early as three days. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2021-09-01 | Code Pharma | Antiviral drug Codivir shows promising effect against COVID-19 codepharma.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CODIVIR | “This is a double-blind, multicentre, multinational study to evaluate the safety and collect preliminary efficacy data of Codivir drug product in 130 hospitalized adults with...” NCT05218356 ↗4“administration of the investigational product CODIVIR/Placebo at a dose of 20 mg twice a day subcutaneously at visits Day0-Day6 (7 days total)” NCT05218356 ↗ “Codivir will be administered in addition to these treatments at a dose of 20 mg SC twice daily for 10 days.” NCT04930861 ↗ “administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.” NCT04930861 ↗ |
| Route | Subcutaneous | “administration of the investigational product CODIVIR at a dose of 20 mg twice a day subcutaneously.” NCT04930861 ↗ |